-
1
-
-
84874909144
-
Agonist antibodies to TNFR molecules that costimulate T and NK cells
-
Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013, 19:1044-1053.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1044-1053
-
-
Melero, I.1
Hirschhorn-Cymerman, D.2
Morales-Kastresana, A.3
Sanmamed, M.F.4
Wolchok, J.D.5
-
2
-
-
84879599112
-
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
-
Callahan MK, Wolchok JD At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013, 94:41-53.
-
(2013)
J Leukoc Biol
, vol.94
, pp. 41-53
-
-
Callahan, M.K.1
Wolchok, J.D.2
-
3
-
-
84884586706
-
Checkpoint modulation in melanoma: an update on ipilimumab and future directions
-
Page DB, Postow MA, Callahan MK, Wolchok JD Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013, 15:500-508.
-
(2013)
Curr Oncol Rep
, vol.15
, pp. 500-508
-
-
Page, D.B.1
Postow, M.A.2
Callahan, M.K.3
Wolchok, J.D.4
-
4
-
-
84893965118
-
Immune modulation in cancer with antibodies
-
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD Immune modulation in cancer with antibodies. Annu Rev Med 2014, 65:185-202.
-
(2014)
Annu Rev Med
, vol.65
, pp. 185-202
-
-
Page, D.B.1
Postow, M.A.2
Callahan, M.K.3
Allison, J.P.4
Wolchok, J.D.5
-
5
-
-
84897854198
-
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer
-
Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014, 9:e89350.
-
(2014)
PLoS One
, vol.9
, pp. e89350
-
-
Guo, Z.1
Wang, X.2
Cheng, D.3
Xia, Z.4
Luan, M.5
Zhang, S.6
-
6
-
-
77954704783
-
Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules
-
Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010, 184:5493-5501.
-
(2010)
J Immunol
, vol.184
, pp. 5493-5501
-
-
Takeda, K.1
Kojima, Y.2
Uno, T.3
Hayakawa, Y.4
Teng, M.W.5
Yoshizawa, H.6
Yagita, H.7
Gejyo, F.8
Okumura, K.9
Smyth, M.J.10
-
7
-
-
84905994658
-
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
-
Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014, 111:11774-11779.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 11774-11779
-
-
Kim, K.1
Skora, A.D.2
Li, Z.3
Liu, Q.4
Tam, A.J.5
Blosser, R.L.6
Diaz, L.A.7
Papadopoulos, N.8
Kinzler, K.W.9
Vogelstein, B.10
-
8
-
-
84893683548
-
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
-
[5876-12-36]
-
Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 2014, 12:36. [5876-12-36].
-
(2014)
J Transl Med
, vol.12
, pp. 36
-
-
Lu, L.1
Xu, X.2
Zhang, B.3
Zhang, R.4
Ji, H.5
Wang, X.6
-
9
-
-
66049113612
-
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
-
Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009, 206:1103-1116.
-
(2009)
J Exp Med
, vol.206
, pp. 1103-1116
-
-
Hirschhorn-Cymerman, D.1
Rizzuto, G.A.2
Merghoub, T.3
Cohen, A.D.4
Avogadri, F.5
Lesokhin, A.M.6
Weinberg, A.D.7
Wolchok, J.D.8
Houghton, A.N.9
-
10
-
-
84927666190
-
The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4
-
Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015, 21:1639-1651.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1639-1651
-
-
Liu, L.1
Mayes, P.A.2
Eastman, S.3
Shi, H.4
Yadavilli, S.5
Zhang, T.6
Yang, J.7
Seestaller-Wehr, L.8
Zhang, S.Y.9
Hopson, C.10
-
12
-
-
2642566088
-
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
-
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
-
(2004)
Pharmacol Rev
, vol.56
, pp. 185-229
-
-
Minotti, G.1
Menna, P.2
Salvatorelli, E.3
Cairo, G.4
Gianni, L.5
-
13
-
-
0033006172
-
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
-
Gewirtz DA A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
-
(1999)
Biochem Pharmacol
, vol.57
, pp. 727-741
-
-
Gewirtz, D.A.1
-
14
-
-
79960426821
-
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors
-
Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011, 71:4809-4820.
-
(2011)
Cancer Res
, vol.71
, pp. 4809-4820
-
-
Mattarollo, S.R.1
Loi, S.2
Duret, H.3
Ma, Y.4
Zitvogel, L.5
Smyth, M.J.6
-
15
-
-
34547102216
-
Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect
-
Zhu S, Waguespack M, Barker SA, Li S Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 2007, 13:4252-4260.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4252-4260
-
-
Zhu, S.1
Waguespack, M.2
Barker, S.A.3
Li, S.4
-
16
-
-
79952716229
-
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy
-
Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011, 208:491-503.
-
(2011)
J Exp Med
, vol.208
, pp. 491-503
-
-
Ma, Y.1
Aymeric, L.2
Locher, C.3
Mattarollo, S.R.4
Delahaye, N.F.5
Pereira, P.6
Boucontet, L.7
Apetoh, L.8
Ghiringhelli, F.9
Casares, N.10
-
17
-
-
84876753532
-
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells
-
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
-
(2013)
Immunity
, vol.38
, pp. 729-741
-
-
Ma, Y.1
Adjemian, S.2
Mattarollo, S.R.3
Yamazaki, T.4
Aymeric, L.5
Yang, H.6
Portela Catani, J.P.7
Hannani, D.8
Duret, H.9
Steegh, K.10
-
18
-
-
33846057130
-
Calreticulin exposure dictates the immunogenicity of cancer cell death
-
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
-
(2007)
Nat Med
, vol.13
, pp. 54-61
-
-
Obeid, M.1
Tesniere, A.2
Ghiringhelli, F.3
Fimia, G.M.4
Apetoh, L.5
Perfettini, J.L.6
Castedo, M.7
Mignot, G.8
Panaretakis, T.9
Casares, N.10
-
19
-
-
41549145181
-
Immunogenicity of anthracyclines: moving towards more personalized medicine
-
Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008, 14:141-151.
-
(2008)
Trends Mol Med
, vol.14
, pp. 141-151
-
-
Apetoh, L.1
Mignot, G.2
Panaretakis, T.3
Kroemer, G.4
Zitvogel, L.5
-
20
-
-
84857789296
-
The secret ally: immunostimulation by anticancer drugs
-
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11:215-233.
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 215-233
-
-
Galluzzi, L.1
Senovilla, L.2
Zitvogel, L.3
Kroemer, G.4
-
21
-
-
0027213484
-
Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes
-
Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993, 53:3964-3967.
-
(1993)
Cancer Res
, vol.53
, pp. 3964-3967
-
-
Williams, S.S.1
Alosco, T.R.2
Mayhew, E.3
Lasic, D.D.4
Martin, F.J.5
Bankert, R.B.6
-
22
-
-
0029741953
-
Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts
-
Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996, 56:3743-3746.
-
(1996)
Cancer Res
, vol.56
, pp. 3743-3746
-
-
Sakakibara, T.1
Chen, F.A.2
Kida, H.3
Kunieda, K.4
Cuenca, R.E.5
Martin, F.J.6
Bankert, R.B.7
-
23
-
-
84902211438
-
A new Bliss independence model to analyze drug combination data
-
Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H A new Bliss independence model to analyze drug combination data. J Biomol Screen 2014, 19:817-821.
-
(2014)
J Biomol Screen
, vol.19
, pp. 817-821
-
-
Zhao, W.1
Sachsenmeier, K.2
Zhang, L.3
Sult, E.4
Hollingsworth, R.E.5
Yang, H.6
-
24
-
-
75749147533
-
Immunogenic death of colon cancer cells treated with oxaliplatin
-
Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
-
(2010)
Oncogene
, vol.29
, pp. 482-491
-
-
Tesniere, A.1
Schlemmer, F.2
Boige, V.3
Kepp, O.4
Martins, I.5
Ghiringhelli, F.6
Aymeric, L.7
Michaud, M.8
Apetoh, L.9
Barault, L.10
-
25
-
-
84913586780
-
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
-
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014, 20(11):1301-1309.
-
(2014)
Nat Med
, vol.20
, Issue.11
, pp. 1301-1309
-
-
Sistigu, A.1
Yamazaki, T.2
Vacchelli, E.3
Chaba, K.4
Enot, D.P.5
Adam, J.6
Vitale, I.7
Goubar, A.8
Baracco, E.E.9
Remedios, C.10
-
26
-
-
0038575243
-
Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells
-
Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 2003, 52:463-472.
-
(2003)
Cancer Immunol Immunother
, vol.52
, pp. 463-472
-
-
Ujhazy, P.1
Zaleskis, G.2
Mihich, E.3
Ehrke, M.J.4
Berleth, E.S.5
-
27
-
-
29144530630
-
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
-
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005, 202:1691-1701.
-
(2005)
J Exp Med
, vol.202
, pp. 1691-1701
-
-
Casares, N.1
Pequignot, M.O.2
Tesniere, A.3
Ghiringhelli, F.4
Roux, S.5
Chaput, N.6
Schmitt, E.7
Hamai, A.8
Hervas-Stubbs, S.9
Obeid, M.10
-
28
-
-
38549148416
-
Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects
-
Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007, 6:880-885.
-
(2007)
Cancer Biol Ther
, vol.6
, pp. 880-885
-
-
Suzuki, E.1
Sun, J.2
Kapoor, V.3
Jassar, A.S.4
Albelda, S.M.5
-
29
-
-
84962258492
-
Three steps to breaking immune tolerance to lymphoma: a microparticle approach
-
Makkouk A, Joshi VB, Lemke CD, Wongrakpanich A, Olivier AK, Blackwell SE, Salem AK, Weiner GJ Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res 2015, 3:389-398.
-
(2015)
Cancer Immunol Res
, vol.3
, pp. 389-398
-
-
Makkouk, A.1
Joshi, V.B.2
Lemke, C.D.3
Wongrakpanich, A.4
Olivier, A.K.5
Blackwell, S.E.6
Salem, A.K.7
Weiner, G.J.8
-
30
-
-
0343923453
-
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
-
Gabizon A, Goren D, Horowitz A, Tzemach D, Lossos A, Siegal T Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997, 24:337-344.
-
(1997)
Adv Drug Deliv Rev
, vol.24
, pp. 337-344
-
-
Gabizon, A.1
Goren, D.2
Horowitz, A.3
Tzemach, D.4
Lossos, A.5
Siegal, T.6
-
31
-
-
0347626100
-
Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model
-
Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003, 63:8408-8413.
-
(2003)
Cancer Res
, vol.63
, pp. 8408-8413
-
-
Hermans, I.F.1
Chong, T.W.2
Palmowski, M.J.3
Harris, A.L.4
Cerundolo, V.5
-
32
-
-
84865553173
-
Combination immunotherapy approaches
-
viii41-viii46
-
Drake CG Combination immunotherapy approaches. Ann Oncol 2012, 23(Suppl. 8):viii41-viii46.
-
(2012)
Ann Oncol
, vol.23
-
-
Drake, C.G.1
-
33
-
-
33746115391
-
CD80 in immune suppression by mouse ovarian carcinoma-associated gr-1 + CD11b + myeloid cells
-
Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RB CD80 in immune suppression by mouse ovarian carcinoma-associated gr-1 + CD11b + myeloid cells. Cancer Res 2006, 66:6807-6815.
-
(2006)
Cancer Res
, vol.66
, pp. 6807-6815
-
-
Yang, R.1
Cai, Z.2
Zhang, Y.3
Yutzy, W.H.4
Roby, K.F.5
Roden, R.B.6
-
34
-
-
33744903142
-
Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
-
Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006, 66:5419-5426.
-
(2006)
Cancer Res
, vol.66
, pp. 5419-5426
-
-
Ewens, A.1
Luo, L.2
Berleth, E.3
Alderfer, J.4
Wollman, R.5
Hafeez, B.B.6
Kanter, P.7
Mihich, E.8
Ehrke, M.J.9
-
35
-
-
84908647719
-
Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study
-
Simpkins F, Flores A, Chu C, Berek JS, Lucci J, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, et al. Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 2013, 1:168-178.
-
(2013)
Cancer Immunol Res
, vol.1
, pp. 168-178
-
-
Simpkins, F.1
Flores, A.2
Chu, C.3
Berek, J.S.4
Lucci, J.5
Murray, S.6
Bauman, J.7
Struemper, H.8
Germaschewski, F.9
Jonak, Z.10
-
36
-
-
73249137169
-
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18
-
[5876-7-104]
-
Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, Carroll RG, Gimotty PA, Hammond R, Danet-Desnoyers GA, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med 2009, 7:104. [5876-7-104].
-
(2009)
J Transl Med
, vol.7
, pp. 104
-
-
Alagkiozidis, I.1
Facciabene, A.2
Carpenito, C.3
Benencia, F.4
Jonak, Z.5
Adams, S.6
Carroll, R.G.7
Gimotty, P.A.8
Hammond, R.9
Danet-Desnoyers, G.A.10
-
38
-
-
78449244037
-
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
-
Di Giacomo AM, Biagioli M, Maio M The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37:499-507.
-
(2010)
Semin Oncol
, vol.37
, pp. 499-507
-
-
Di Giacomo, A.M.1
Biagioli, M.2
Maio, M.3
|